Ruxolitinib

Catalog Number	ACM941678495-1
CAS Number	941678-49-5
Synonyms	Ruxolitinib (INCB018424)
IUPAC Name	(3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
Molecular Weight	306.37
Molecular Formula	C17H18N6
Canonical SMILES	C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI	InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
InChI Key	HFNKQEVNSGCOJV-OAHLLOKOSA-N
Purity	98%+
Storage	Store in dry, low temperature, sealed, 2-8 °C.
Complexity	453
Exact Mass	306.15929460
Heavy Atom Count	23
Isomeric SMILES	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
Monoisotopic Mass	306.15929460
Topological Polar Surface Area	83.2Ų

Custom Q&A

What is the chemical structure of Ruxolitinib?

Ruxolitinib has a molecular formula of C17H18N6.

What is the melting point of Ruxolitinib?

The melting point of Ruxolitinib is 84-89°C.

What are the most common side effects of Ruxolitinib?

The most common side effects of Ruxolitinib are lower platelet counts and anemia, as well as bruising, dizziness, and headache.

What is the primary pharmacological effect of Ruxolitinib?

Ruxolitinib is a potent and selective JAK1 and JAK2 inhibitor, with anti-tumor and immunomodulatory activities.

What type of disease is Ruxolitinib approved to treat?

Ruxolitinib is approved for the treatment of myelofibrosis, which is a type of myelodysplastic disorder.

What is the dosage recommendation for Ruxolitinib?

The initial dosage of Ruxolitinib is 20 mg twice per day for patients with platelet counts over 200/μl.

How does Ruxolitinib inhibit the JAK-signal transducer and activator of transcription pathway?

By inhibiting JAK1 and JAK2, Ruxolitinib downregulates the JAK-STAT pathway, reducing myeloproliferation, inducing apoptosis, and decreasing cytokine plasma levels.

What is the brand name of Ruxolitinib?

The brand name of Ruxolitinib is Jakafi.

What kinase does Ruxolitinib target?

Ruxolitinib targets JAK1.

What clinical research has been conducted on Ruxolitinib outside of myelofibrosis treatment?

A study conducted at Columbia University Medical Center found that Ruxolitinib could help alleviate symptoms of alopecia areata in human test subjects.

※ Please kindly note that our products are for research use only.